Related news from |
Tue, 14 May 2024 16:56:00 +0000 |
Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag
Allogene (ALLO) reports drab first-quarter 2024 results. The company secures the development and marketing rights to its CD19 oncology program in Europe.
|
Tue, 14 May 2024 14:02:00 +0000 |
Novo Nordisk (NVO) Up 3% as Haemophilia Drug Meets Study Goals
Novo Nordisk's (NVO) shares rise 3.1% as the company meets co-primary endpoints in a late-stage study evaluating its investigational candidate, Mim8, for the treatment of haemophilia A.
|
Tue, 14 May 2024 13:25:00 +0000 |
Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
Merck (MRK) discontinues the Keytruda plus vibostolimab co-formulation arm of a phase III study due to a higher rate of patient discontinuation.
|
Tue, 14 May 2024 12:57:00 +0000 |
Bayer (BAYRY) Q1 Earnings Fall Y/Y on Lower Product Sales
Bayer's (BAYRY) Q1 earnings and sales decline year over year due to a fall in volumes for non-glyphosate-based herbicides and lower prices for glyphosate-based products in the Crop Science division.
|
Mon, 13 May 2024 16:00:11 +0000 |
Ligand (LGND) Moves to Strong Buy: Rationale Behind the Upgrade
Ligand (LGND) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
|
Mon, 13 May 2024 15:25:00 +0000 |
Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
Moderna's (MRNA) RSV vaccine, mRNA-1345's review timeline gets delayed. A decision is now expected by the end of May.
|
Mon, 13 May 2024 15:16:00 +0000 |
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.
|
Fri, 10 May 2024 15:33:00 +0000 |
Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates
Nektar (NKTR) reports a narrower-than-expected loss in the first quarter of 2024 and tops revenue estimates.
|
Fri, 10 May 2024 15:14:00 +0000 |
Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates
Insmed (INSM) Q1 earnings beat estimates while sales miss the mark. Management posts positive data readouts from mid-stage studies on its experimental inhalation powder in PH-ILD and PAH indications.
|
Fri, 10 May 2024 14:58:00 +0000 |
Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates
Iovance (IOVA) reports mixed first-quarter results. Shares gain on encouraging initial demand for the recently-approved melanoma drug Amtagvi in the United States.
|
Fri, 10 May 2024 14:46:00 +0000 |
Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated
Amicus (FOLD) reports first-quarter 2024 results, wherein earnings beat the Zacks Consensus Estimate but sales miss the same. The company updates its financial guidance for 2024.
|
Fri, 10 May 2024 12:50:07 +0000 |
Ligand (LGND) Is a Great Choice for 'Trend' Investors, Here's Why
Ligand (LGND) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
|
Thu, 09 May 2024 15:40:00 +0000 |
Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues
Catalyst (CPRX) reports first-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, driven by strong Firdapse sales.
|
Thu, 09 May 2024 14:58:00 +0000 |
CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss
CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.
|
Thu, 09 May 2024 13:40:11 +0000 |
Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year?
Here is how Ligand Pharmaceuticals (LGND) and Adverum Biotechnologies (ADVM) have performed compared to their sector so far this year.
|
Thu, 09 May 2024 11:26:23 +0000 |
Ligand Pharmaceuticals First Quarter 2024 Earnings: EPS: US$4.86 (vs US$2.56 in 1Q 2023)
Ligand Pharmaceuticals ( NASDAQ:LGND ) First Quarter 2024 Results Key Financial Results Revenue: US$31.0m (down 30...
|
Thu, 09 May 2024 09:59:00 +0000 |
Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss
Acadia's (ACAD) earnings in the first quarter of 2024 beat the Zacks Consensus Estimate, while revenues miss the same.
|
Wed, 08 May 2024 17:22:24 +0000 |
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript May 7, 2024 Ligand Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.75, expectations were $1.13. LGND isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by. Our […]
|
Wed, 08 May 2024 16:20:00 +0000 |
Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues
Esperion's (ESPR) first-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.
|
Wed, 08 May 2024 16:19:00 +0000 |
Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates
Ligand Pharmaceuticals (LGND) reports mixed first-quarter results. Management reiterates the 2024 financial outlook.
|